CP 690550 citrate (Tofacitinib citrate)

(HB1427)
Technical documents: SDS Datasheet

Product overview

Name CP 690550 citrate (Tofacitinib citrate)
Alternative names Tofacitinib citrate
Purity >99%
Description Potent JAK inhibitor
Write Your Own Review
You're reviewing:CP 690550 citrate (Tofacitinib citrate)
Rate this item:

Biological Data

Biological description Potent JAK inhibitor. Inhibits JAK3, JAK2 and JAK1 (IC50 values are 1, 20 and 112 nM respectively). Reduces pro-inflammatory cytokine release. Shows immunosuppressant actions.

Solubility & Handling

Solubility overview Soluble in DMSO (100mM)
Storage instructions +4°C
Storage of solutions Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >99%
Chemical name (3R,4R)-4-Methyl-3-(methyl-7H-pyrro lo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepro panenitrile citrate
Molecular Weight 504.49
Chemical structure CP 690550 citrate  [540737-29-9] Chemical Structure
Molecular Formula C16H20N6O.C6H8O7
CAS Number 540737-29-9
PubChem identifier 10174505
SMILES C[C@H]1[C@@H](N(C2=NC=NC3=C2C=CN3)C)CN(C(CC#N)=O)CC1.OC(CC(O)=O)(C(O)=O)CC(O)=O
InChiKey SYIKUFDOYJFGBQ-YLAFAASESA-N

References for CP 690550 citrate (Tofacitinib citrate)

References are publications that support the biological activity of the product
  • CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term Therapeutic Effects in an SKG Arthritis Model.

    Oh K et al (2013) Immune Netw 13(6) : 257-63.
  • Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

    Flanagan ME et al (2010) J Med Chem 53(24) : 8468-84.
  • Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).

    Jiang JK et al (2008) J Med Chem 51(24) : 8012-8.

3 Item(s)